<DOC>
	<DOCNO>NCT01119768</DOCNO>
	<brief_summary>To compare symptom control rate 8 week esomeprazole treatment regimen group 2 week esomeprazole treatment regimen group co-diagnosed NERD chronic gastritis patient , evaluate GerdQ 24 week maintenance treatment/follow .</brief_summary>
	<brief_title>Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease ( NERD ) Chronic Gastritis Patients</brief_title>
	<detailed_description>A multicenter , randomize , open-label Phase IV study explore symptom control rate co-diagnosed NERD chronic gastritis patient treat 8 week esomeprazole treatment regimen 2 week esomeprazole treatment regimen .</detailed_description>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Gastritis , Atrophic</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Heartburn and/or regurgitation symptom last least 3 month Endoscopic diagnose chronic gastritis ( nonatrophic , mild atrophic gastritis ) within 2 week prior randomization GerdQ score =8 Endoscopic visible reflux esophagitis , esophageal varix , Barrett 's esophagus , malignancy peptic ulcer Patients Hp positive result eager take Hp eradication therapy exclude If Hp positive , patient could take Hp eradication therapy study completion Previous PPI H2RA therapy last 2 week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>GI</keyword>
	<keyword>Nexium</keyword>
	<keyword>Phase IV</keyword>
	<keyword>Co-diagnosed NERD</keyword>
</DOC>